Fact sheet: Polar Capital Healthcare Opp

Fund information
Fund name
Polar Capital Healthcare Opportunities I GBP
Fund manager company
Polar Capital
Fund type
OEIC
Fund managers
  • Daniel Mahonysince 30/11/2007
  • Gareth Powellsince 30/11/2007
Fund objective
The Fund aims to preserve capital and achieve long-term growth by investing in a globally-diversified portfolio of companies within the healthcare industry.
Benchmark
  • MSCI ACWI Health Care Index
Investment style
Active,Growth
Investment method
Shares
Quick stats
1 Year return
13%
1 Year rank in sector
8/30
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.21%
Fund size
£1,504m (£1,263m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
135
Top in this sector
Fund name1 Year
CSIF 2CS(L)GblDglHthEq24.4%
Variopartner SICAV SeBiOpp24.2%
Polar Capital Biotechnology19.5%
Variopartner SICAV MVGbMdtcF18.3%
BB Medtech16.9%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA75.8%
    UK13.1%
    Money Market4.3%
    Germany3.5%
    Sweden2.4%
  • Healthcare & Medical Products33.8%
    Biotechnology/Medical28.3%
    Health Care21.7%
    Pharmaceuticals12%
    Money Market4.3%
  • US Equities75.8%
    UK Equities13.1%
    Money Market4.3%
    German Equities3.5%
    Swedish Equities2.4%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund7.1%7.4%7.7%13%25.9%125.5%
Sector2.9%1.7%5%8.6%-0.1%68.8%
Rank within sector2 / 314 / 308 / 308 / 304 / 281 / 21
Quartile1st1st2nd2nd1st1st
Calendar performance
 YTD - 20182017201620152014
Fund6.6%13.6%4.6%13.4%34.8%
Sector3.2%14.9%-9.9%7.2%28.1%
Rank within sector7 / 3020 / 295 / 296 / 2510 / 22
Quartile1st3rd1st1st2nd
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
7.34
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.62
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.24
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
13.4
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
11.34
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
0.66
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.49
Price movement
52 week high33.13
52 week low29.32
Current bid price-
Current offer price-
Current mid price33.13
Region
1USA75.85%
2UK13.13%
3Money Market4.3%
4Germany3.46%
5Sweden2.39%
6Canada0.88%
Industry sector
1Healthcare & Medical Products33.83%
2Biotechnology/Medical28.25%
3Health Care21.66%
4Pharmaceuticals11.96%
5Money Market4.3%
Asset type
1US Equities75.8%
2UK Equities13.1%
3Money Market4.3%
4German Equities3.5%
5Swedish Equities2.4%
6Canadian Equities0.9%
Individual holdings
1ABBOTT LABORATORIES4.75%
2MERCK & CO INC(NEW)4.61%
3ASTRAZENECA PLC3.72%
4STRYKER CORP3.71%
5EDWARDS LIFESCIENCES CORP3.64%
6FRESENIUS MEDICAL CARE AG & CO.KGAA3.46%
7BAXTER INTERNATIONAL INC3.44%
8HCA HEALTHCARE INC3.42%
9LOXO ONCOLOGY INC3.42%
Management
Fund manager group
Polar Capital
Fund manager company
Polar Capital
Fund type
OEIC
Fund objective
The Fund aims to preserve capital and achieve long-term growth by investing in a globally-diversified portfolio of companies within the healthcare industry.
Benchmark
  • MSCI ACWI Health Care Index
Investment style
Active,Growth
Investment method
Shares
Fund managers
NameSinceBiography
Daniel Mahony30/11/2007Daniel joined Polar Capital to set up the healthcare team in 2007. Prior to joining Polar Capital, he was head of the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Daniel worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. Daniel received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.
Gareth Powell30/11/2007Gareth joined Polar Capital in 2007 to set up the healthcare team. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he began managing the Framlington Health Fund and in 2002 he helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Distributor Status, IA Recognised, Reporting Fund Status, UCITS V Compliant
Domicile
No data available.
Fund for sale in
Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Guernsey, Ireland, Italy, Jersey, Liechtenstein, Luxembourg, Netherlands, Norway, Offshore, Singapore, Sweden
Polar Capital Healthcare Opportunities EUR
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price25.3
CurrencyEUR
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBDN1
Polar Capital Healthcare Opportunities GBP
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISAYes
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price22.1
CurrencyGBP
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBDN0
Polar Capital Healthcare Opportunities I EUR
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.21%
Total expense ratio (TER)1.21%
Bid price-
Offer price-
Mid price37.93
CurrencyEUR
Price updated17/05/2018
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeGLG7
Polar Capital Healthcare Opportunities I GBP
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISAYes
Ongoing charge (OCF)1.21%
Total expense ratio (TER)1.21%
Bid price-
Offer price-
Mid price33.13
CurrencyGBP
Price updated17/05/2018
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeGLG6
Polar Capital Healthcare Opportunities I USD
Initial charge5%
Annual charge1%
Min single investment£1,000,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.21%
Total expense ratio (TER)1.21%
Bid price-
Offer price-
Mid price44.73
CurrencyUSD
Price updated17/05/2018
TypeIncome
Institutional or retail classInstitutional
Domicile-
Citi codeGLG5
Polar Capital Healthcare Opportunities R EUR
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price36.33
CurrencyEUR
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeGLH0
Polar Capital Healthcare Opportunities R GBP
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price31.73
CurrencyGBP
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeGLG9
Polar Capital Healthcare Opportunities R USD
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price42.85
CurrencyUSD
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeGLG8
Polar Capital Healthcare Opportunities USD
Initial charge5%
Annual charge1.5%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.71%
Total expense ratio (TER)1.71%
Bid price-
Offer price-
Mid price29.84
CurrencyUSD
Price updated17/05/2018
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeBDM9
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.